AU2002365622A1 - Novel glucagon antagonists - Google Patents

Novel glucagon antagonists

Info

Publication number: AU2002365622A1
Authority: AU; Australia
Prior art keywords: glucagon antagonists; novel glucagon; novel; antagonists; glucagon
Prior art date: 2001-12-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002365622A

Inventor

Inge Thoger Christensen

Anker Steen Jorgensen

Janos Tibor Kodra

Jesper Lau

Peter Madsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-03

Filing date

2002-11-28

Publication date

2003-06-17

2002-11-28 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

2003-06-17 Publication of AU2002365622A1 publication Critical patent/AU2002365622A1/en

Status Abandoned legal-status Critical Current

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Furan Compounds (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

AU2002365622A 2001-12-03 2002-11-28 Novel glucagon antagonists Abandoned AU2002365622A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200101789		2001-12-03
DKPA200101789		2001-12-03
DKPA200201117		2002-07-18
DKPA200201117		2002-07-18
PCT/DK2002/000800 WO2003048109A1 (en)	2001-12-03	2002-11-28	Novel glucagon antagonists

Publications (1)

Publication Number	Publication Date
AU2002365622A1 true AU2002365622A1 (en)	2003-06-17

Family

ID=26069105

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002365622A Abandoned AU2002365622A1 (en)	2001-12-03	2002-11-28	Novel glucagon antagonists

Country Status (4)

Country	Link
EP (1)	EP1463715A1 (en)
JP (1)	JP2005511683A (en)
AU (1)	AU2002365622A1 (en)
WO (1)	WO2003048109A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004210127B2 (en)	2003-01-27	2009-10-01	Merck Sharp & Dohme Corp.	Substituted pyrazoles, compositions containing such compounds and methods of use
US7989457B2 (en)	2004-05-28	2011-08-02	Eli Lilly And Company	Glucagon receptor antagonists, preparation and therapeutic uses
SI1758853T1 (en) *	2004-06-14	2010-05-31	Lilly Co Eli	Glucagon receptor antagonists, preparation and therapeutic uses
US7622491B2 (en) *	2004-08-13	2009-11-24	Metabolex Inc.	Modulators of PPAR and methods of their preparation
WO2006086488A2 (en)	2005-02-11	2006-08-17	Eli Lilly And Company	Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
CA2600159A1 (en)	2005-03-21	2006-09-28	Merck & Co., Inc.	Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en)	2005-03-30	2010-09-28	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP1962820A2 (en) *	2005-06-24	2008-09-03	DSMIP Assets B.V.	Medicament for the treatment of impaired glucose metabolism
AU2006276072A1 (en)	2005-07-26	2007-02-08	Merck Sharp & Dohme Corp.	Process for synthesizing a substituted pyrazole
TW200745031A (en)	2005-10-13	2007-12-16	Merck & Co Inc	Acyl indoles, compositions containing such compounds and methods of use
BRPI0618349A2 (en)	2005-11-17	2011-08-23	Lilly Co Eli	pharmaceutically acceptable compound or salt thereof, pharmaceutical composition, and use of a compound or salt thereof
CA2629223C (en)	2005-11-17	2013-08-06	Eli Lilly And Company	Glucagon receptor antagonists, preparation and therapeutic uses
DK1951659T3 (en)	2005-11-18	2010-10-11	Lilly Co Eli	Glucagon Receptor Antagonists, Preparation and Therapeutic Use thereof
CN101312723B (en)	2005-11-22	2012-01-11	伊莱利利公司	Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0618745A2 (en) *	2005-11-23	2011-09-13	Lilly Co Eli	compound or a salt thereof, pharmaceutical composition, and use of a compound or a salt thereof
JP2009530381A (en)	2006-03-23	2009-08-27	メルクエンドカムパニーインコーポレーテッド	Glucagon receptor antagonist compounds, compositions containing the compounds and methods of use
JP2009537525A (en)	2006-05-16	2009-10-29	メルクエンドカムパニーインコーポレーテッド	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en)	2006-10-03	2008-05-16	Merck & Co Inc	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2129654B1 (en) *	2007-02-09	2014-05-28	Metabasis Therapeutics, Inc.	Antagonists of the glucagon receptor
US8309580B2 (en)	2007-11-01	2012-11-13	Takeda Pharmaceutical Company Limited	Heterocyclic compound
MY158982A (en) *	2008-03-05	2016-11-30	Takeda Pharmaceuticals Co	Heterocyclic compound
EP2291358B1 (en) *	2008-05-16	2018-03-28	Merck Sharp & Dohme Corp.	Glucagon receptor antagonists, compositions, and methods for their use
ES2714207T3 (en) *	2008-08-13	2019-05-27	Metabasis Therapeutics Inc	Glucagon antagonists
CN101768149B (en) *	2008-12-30	2013-10-30	成都地奥制药集团有限公司	Beta- aminoketone (alkamine) derivatives and use thereof
WO2010088061A1 (en)	2009-01-28	2010-08-05	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
UY32088A (en) *	2009-02-06	2010-08-31	Takeda Pharmaceutical	HETEROCICLICAL COMPOUND
WO2011027849A1 (en) *	2009-09-04	2011-03-10	武田薬品工業株式会社	Heterocyclic compound
CA2822017C (en)	2010-12-23	2015-04-07	Pfizer Inc.	Glucagon receptor modulators
LT2673260T (en)	2011-02-08	2016-10-25	Pfizer Inc.	Glucagon receptor modulator
EP2714647B1 (en) *	2011-05-23	2015-04-29	Janssen Pharmaceutica, N.V.	Biphenyl derivatives useful as glucagon receptor antagonists
EP2714661B1 (en) *	2011-05-23	2015-09-30	Janssen Pharmaceutica, N.V.	Picolinamido - propanoic acid derivatives useful as glucagon receptor antagonists
BR112014000288A2 (en)	2011-07-22	2017-01-10	Pfizer	quinolinyl glucagon receptor modulators
US9725427B2 (en)	2012-03-16	2017-08-08	Biohaven Pharmaceutical Holding Company Limited	Prodrugs of riluzole and their method of use
JP6401189B2 (en)	2013-02-22	2018-10-03	サミュメッドリミテッドライアビリティカンパニー	Γ-diketones as activators of Wnt / β-catenin signaling pathway
WO2015066252A1 (en)	2013-11-04	2015-05-07	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions thereof, and methods of use
JP2017519000A (en)	2014-06-12	2017-07-13	リガンド・ファーマシューティカルズ・インコーポレイテッド	Glucagon antagonist
CN107205970A (en) *	2014-11-05	2017-09-26	弗莱塞斯生物科学公司	Immunomodulator
WO2017215586A1 (en) *	2016-06-14	2017-12-21	浙江海正药业股份有限公司	Amide derivatives, preparation process thereof and use thereof in medicine
EA201991731A1 (en)	2017-01-27	2019-12-30	Женфит	ROR – GAMMA MODULATORS AND THEIR APPLICATION
TW202003453A (en)	2018-02-13	2020-01-16	美商利根德製藥公司	Glucagon receptor antagonists
CN110357813A (en) *	2018-04-09	2019-10-22	信达生物制药(苏州)有限公司	A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613942B1 (en) *	1997-07-01	2003-09-02	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
AU2001265834A1 (en) *	2000-06-23	2002-01-08	Novo Nordisk A/S	Glucagon antagonists/inverse agonists

2002
- 2002-11-28 EP EP02804158A patent/EP1463715A1/en not_active Withdrawn
- 2002-11-28 JP JP2003549302A patent/JP2005511683A/en not_active Withdrawn
- 2002-11-28 AU AU2002365622A patent/AU2002365622A1/en not_active Abandoned
- 2002-11-28 WO PCT/DK2002/000800 patent/WO2003048109A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP1463715A1 (en)	2004-10-06
JP2005511683A (en)	2005-04-28
WO2003048109A1 (en)	2003-06-12

Publication	Publication Date	Title
AU2002365622A1 (en)	2003-06-17	Novel glucagon antagonists
AU2001255798A1 (en)	2001-11-12	Glucagon antagonists
AU2002341834A1 (en)	2003-04-07	Antagonists
AU2002360508A1 (en)	2003-06-23	Substituted hydroxyethylamines
SI1671949T1 (en)	2008-10-31	Substituted Pyridinylamines
AU2002367404A1 (en)	2003-07-24	Redox-switchable materials
AU2002367336A1 (en)	2003-07-24	Stairway
AU2003291959A1 (en)	2004-07-14	Novel glucagon antagonists
AU2002359320A1 (en)	2003-05-12	Novel anit-infectives
AU2002365655A1 (en)	2003-06-17	5-ht7 receptor antagonists
AU2002251024A1 (en)	2003-03-20	Substituted fluoroalcoxyphenylsulfonylurea
PL362643A1 (en)	2004-11-02	Substituted fluoroalcoxyphenylsulfonylurea
AU2002321215A1 (en)	2003-05-22	Substituted 4-aminocyclohexanols
SI1406858T1 (en)	2009-12-31	Substituted 4-aminocyclohexanols
AU2002241899A1 (en)	2002-09-12	Tip39 polypeptides
AU2002247861A1 (en)	2002-10-28	Modified calcitonin
AU2002346030A1 (en)	2003-01-21	Novel receptors
WO2002077001A9 (en)	2013-10-31	Novel receptors
PL364601A1 (en)	2004-12-13	Substituted benzo-nitro-heterocycles
AU2001100406A4 (en)	2001-11-01	DriverSMS
AUPR918701A0 (en)	2001-12-20	Tile
AU2002346278A1 (en)	2003-02-17	Tile
AU2002360933A1 (en)	2003-05-19	Antagonists for alpha4-integrins
AU2002311774A1 (en)	2002-10-08	Novel receptors
AU2002310084A1 (en)	2002-12-03	Ccr4 antagonists

Legal Events

Date	Code	Title	Description
2004-08-19	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase